The Global Beta-lactam and Beta-lactamase Inhibitors Market size is estimated to be USD 27.85 billion in 2019 and is predicted to reach USD 37.33 billion by 2030 with a CAGR of 2.7% from 2020-2030.
Beta-lactam Inhibitors is a class of antibiotics which contains beta ring in their molecular structure and helps in to fight against infection based by bacteria and protozoa, these drugs either kill the bacteria or prevents the bacterial growth and cure the infections. Some of the Beta lactam antibiotics are penicillin, cephalosporin and others. Beta-lactamase inhibitors are the drug class which block the activity of beta lactamase enzyme and prevents the degradation of beta lactam.
Request sample copy of this report at: https://www.nextmsc.com/beta-lactam-beta-lactamase-inhibitors-market/request-sample
Market Dynamics and Trends:
There have been increase in modernization and improvement in the healthcare infrastructure coupled with technological advancement over the forecast period. Furthermore, increased prevalence of infectious disease coupled with increased consumption of such drugs in the developing economies are expected to promote the growth of beta-lactam and beta-lactamase inhibitors market over the forecast period.
Other factors include increase in clinical trials of such drugs and developments of new approaches for the treatment of infectious disease are further expected to augment the market growth. However, increase in antibiotic resistance and easy availability over the counter can led to misuse can inhibit the growth of beta-lactam and beta-lactamase inhibitors market. On the other hand, discovery on novel molecule, increased inclination towards combination therapy and huge product pipeline led to new product launches in the beta-lactam and beta-lactamase inhibitors market which are further expected to create ample opportunities in the market.
Market Segmentations and Scope of the Study:
The global beta-lactam and beta-lactamase inhibitors market share is analyzed on the basis of drug class, disease, route of administration, and geography. On the basis of drug class, the market is segmented into Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination. The combination drug class is further sub segmented into Penicillin/Beta Lactamase Inhibitors, Cephalosporins/Beta Lactamase Inhibitors, and Carbapenems/Beta Lactamase Inhibitors. On the basis of disease, the market is divided into Urinary Tract Infection (excluding cUTI), Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, blood stream infection and others. Nosocomial Pneumonia is further sub segmented into Hospital Acquired Pneumonia, Ventilator Associated Pneumonia, and Other. Based on route of administration, the market is fragmented into oral, intravenous and others. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.
Ask for Inquiry at: https://www.nextmsc.com/beta-lactam-beta-lactamase-inhibitors-market/inquire-before-buying
Geographical Analysis:
North America is expected to hold the major market share owing to the presence of well established healthcare facilities and infrastructure coupled with increased adoption of beta-lactam and beta-lactamase inhibitors. Furthermore, development of novel molecules and increased awareness coupled with increase in clinical trials are further expected to support the growth of beta-lactam and beta-lactamase inhibitors market.
Asia Pacific is expected to show rapid growth over the forecast period with persistent growth in market share over the forecast period. Moreover, increased prevalence of infectious disease coupled with increased consumption of such drugs is anticipated to support the growth of beta-lactam and beta-lactamase inhibitors market.
Competitive Landscape:
The beta-lactam and beta-lactamase inhibitors market, which is highly competitive, consists of various market players. Some of the major market players include Allergan Plc., Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Mylan N.V., Merck & Co. Inc., Pfizer Inc., Novartis International AG (Sandoz), Teva Pharmaceutical Industries Ltd. and Sanofi among others.
In the recent past there have been various developments taken place and in near future further takes place which is further expected to enhance the market growth over the forecast period. For instance, in February 2019, Novartis has received the FDA approval for Egaten (triclabendazole) for the treatment of fascioliasis (liver fluke infestation).
Key Benefits:
The beta-lactam and beta-lactamase inhibitors market report provides a quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on.
The study comprises a deep dive analysis of the beta-lactam and beta-lactamase inhibitors market trend including current and future trends for depicting the prevalent investment pockets in the market.
The report provides detailed information related to key drivers, restraints, opportunities and their impact on the beta-lactam and beta-lactamase inhibitors market.
The report incorporates a competitive analysis of the market players along with their market share in the global beta-lactam and beta-lactamase inhibitors market.
The study elaborates SWOT analysis and Porters Five Forces model for the beta-lactam and beta-lactamase inhibitors market.
Value chain analysis in the beta-lactam and beta-lactamase inhibitors market study provides a clear picture of the stakeholders’ roles.
About Next Move Strategy Consulting:
Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.
For more insights, please visit, https://www.nextmsc.com